Home/Pipeline/Oncology PTP/GPCR Program

Oncology PTP/GPCR Program

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Camino Pharma

About Camino Pharma

Camino Pharma is a private, preclinical-stage biotech company pioneering novel allosteric modulators for oncology and neuropsychiatric disorders. Its core expertise lies in targeting historically difficult protein classes like PTPs and GPCRs, with programs in cancer signaling, addiction, and treatment-resistant depression. The company is led by a seasoned founder-CEO with a track record of venture fundraising and drug development, and it maintains strong academic ties with the Sanford Burnham Prebys Medical Discovery Institute. While still pre-revenue, it has secured non-dilutive grant funding from the National Institute on Drug Abuse (NIDA) for its addiction program.

View full company profile

Therapeutic Areas

Oncology Central Nervous System (CNS) Disorders

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active